Next Phase Newsletter

A privately owned fund based in London, United Kingdom, seeks to invest in life science companies with significant growth potential. The initial investment typically ranges from £500,000 to £2,000,000 for equity investments with reserved capital for follow-on investments. The firm also provides standby loans of up to £1,000,000. The firm only invests in companies that are based in the UK.

The firm will consider investments in the life sciences across all sectors including Medical Devices, Therapeutics, Diagnostics, Healthcare-IT and platform technologies. The firm is completely opportunistic in terms of subsector and indication. The firm is open to consider companies in all stages of development from pre-clinical stage all through to commercialization stage.

The firm focuses on private companies with a sizeable and clearly defined target market. The firm is looking to be an active investor, usually taking a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based healthcare investment firm has launched a new US$100M VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, health care IT and services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm backed by a single LP looks to make growth-stage investments in the form of preferred equity, ranging from $1M-$5M initially, with additional capital reserved for follow-on financings, typically up to $10M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 2-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.

The firm makes about one-half of its investments in healthcare, and is open to any healthcare companies that do not require FDA approval for their product/service. However, the firm focuses on B2B-oriented healthcare services and healthcare IT solutions. Some of the firm’s recent healthcare investments include a mobile telemedicine triage service company that provides mobile diabetic retinopathy eye exams as well as an EMR system to help orthopedic surgeons increase productivity.

The firm typically looks for growing companies with a run rate of $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and will work with first-time entrepreneurs. The firm looks to take a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in London, UK with an exclusive focus on healthcare seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

The firm is sub-sector and indication agnostic, but intends to focus on innovative medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience. The firm will consider companies with products in the clinic as long as the company has at least one product that is on the market. The firm prefers to invest in companies who are headquartered or have a large presence in Europe. U.S.-based companies with a European angle will also be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm based in China is focused on medical and health industry investments. The fund is currently investing from its RMB 687 million (USD 100 million) fund. Typical allocation ranges from USD 2 -20 million in companies from Angel, Series A to Pre-IPO rounds. The firm has invested in 12 companies – 5 in medical devices, 6 in biotech and pharma, and 1 in online education. The firm is seeking opportunities from across the world with a focus on China, USA, and Israel.

The firm is opportunistic across sectors including biotechnology and pharmaceutical, medical devices, mobile medical technologies and medical services. The fund is stage agnostic.

The firm is looking for experienced teams with passion and competence, who can deliver innovative, advanced, and market-oriented technology with huge business potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Family Office based in the Southeast USA makes investments via 2 venture funds and a number of private capital accounts. The firm looks to make equity investments generally in series A and B rounds of approximately $1.0 – $1.5 million in rounds totaling $3-$7 million. The firm is open to investing into companies located throughout the United States and makes approximately 2-4 new investments per year.

Within life sciences, the firm is most interested in companies in the medical device and diagnostics space. The firm is looking for companies that have a 510k regulatory pathway with at least a working prototype of the product and preferably some in-human data. The firm is generally open to all indications with particular interested in oncology, rare cancers, diabetes, neurology, ophthalmology and cardiology. The firm is especially interested in CLIA lab diagnostics, software enabled devices, molecular diagnostics for rare cancers and diseases, and algorithms that interpret genetic information and recommend treatment options. The firm is also interested in nutraceuticals, expedited drug development, HIT and business to business technology companies although these areas are less of a focus.

The firm is looking for private companies with experienced management team and looks to take a board seat following investment. The firm looks to be a hands on investor and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Life Science focused investment fund based in China serves as an internal funding vehicle for a major medical group.  The firm primarily considers investments based in China or has a significant China nexus, for example, the company must have a principal market in China, or R&D/manufacturing/sales in China. The fund prefers to follow and take minority stakes. Investment size varies but typically ranges from US$1-4 million. The fund prefers business models that are marketing/sales oriented (vs. technology oriented). The fund is actively seeking new investment opportunities.

Currently the firm is looking for innovative antibiotics or alternatives to antibiotics in human health, animal health, and agriculture. For the stage of development, the fund seeks products that are able to enter the market within 2 years post investment.

The firm seeks an experienced management team that “has done it before.” The fund will consider US-based companies as long as the China nexus criteria is met. The firm seeks to make minority investment and typically requires China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com